Abstract
Acute megakaryoblastic leukemia (AMKL) is a heterogeneous disease with a relatively poorly understood pathogenesis. In this issue of Cancer Cell, Thirant and colleagues systematically examine unique transcriptional and functional effects of ETO2-GLIS2, an oncogenic fusion protein frequently encountered in AMKL, and elucidate a therapeutic vulnerability in this poor-prognosis leukemia.
Original language | English (US) |
---|---|
Pages (from-to) | 307-308 |
Number of pages | 2 |
Journal | Cancer Cell |
Volume | 31 |
Issue number | 3 |
DOIs | |
State | Published - Mar 13 2017 |
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research